DK2682126T3 - GNA1870-baserede vesikelvacciner til bredspektret beskyttelse mod sygdomme forårsaget af Neisseria meningitidis - Google Patents

GNA1870-baserede vesikelvacciner til bredspektret beskyttelse mod sygdomme forårsaget af Neisseria meningitidis Download PDF

Info

Publication number
DK2682126T3
DK2682126T3 DK13172134.2T DK13172134T DK2682126T3 DK 2682126 T3 DK2682126 T3 DK 2682126T3 DK 13172134 T DK13172134 T DK 13172134T DK 2682126 T3 DK2682126 T3 DK 2682126T3
Authority
DK
Denmark
Prior art keywords
gly
ala
leu
lys
ser
Prior art date
Application number
DK13172134.2T
Other languages
English (en)
Inventor
Dan M Granoff
Victor Hou
Original Assignee
Children's Hospital & Res Center At Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital & Res Center At Oakland filed Critical Children's Hospital & Res Center At Oakland
Application granted granted Critical
Publication of DK2682126T3 publication Critical patent/DK2682126T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Claims (17)

1. Sammensætning til anvendelse i en fremgangsmåde til hos et pattedyrindivid at fremkalde anti-GNA1870-polypeptid-antistoffer, der er baktericide for mindst tre Neisseria meningitidis-stammer, der er heterologe for PorA, hvilken sammensætning omfatter: isolerede antigen-vesikler fra en første Neisseria meningitidis-baktene, hvor Neisseria meningitidis-bakterien er genmodificeret til at overeksprimere et GNA1870-polypeptid på et niveau, der er højere end tre gange et niveau af GNA1870-polypeptidet eksprimeret i en parentalstamme, hvorfra den første Neisseria meningitidis-baVXene er afledt, og en farmaceutisk acceptabel bærer, hvor vesiklerne, når de indgives til individet, fremkalder de anti-GNA1870-polypeptid-antistoffer, der er baktericide for mindst tre Neisseria meningitidis-stammer, der er heterologe for PorA.
2. Sammensætning til anvendelse ifølge krav 1, hvor vesiklerne er ydre membran-vesikler (OMV'er), mikrovesikler (MV'er) eller en blanding af OMV-er og MV'er.
3. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-2, hvor den første Neisseria meningitidis- bakterie er gen modificeret til at tilsikre ekspression af det overeksprimerede GNA1870-polypeptid fra en heterolog promoter.
4. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor den første Neisseria meningitidis-baktene er gen modificeret til at forstyrre produktionen af et endogent GNA1870-polypeptid.
5. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor det overeksprimerede GNA1870-polypeptid er heterologt til den første Neisseria meningitidis-bakterie.
6. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-5, hvor sammensætningen omfatter et isoleret Neisseria-antigen.
7. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-5, hvor den første Neisseria meningitidis-bakterie er genmodificeret til at ek-sprimere yderligere antigener af interesse.
8. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-7, hvor den første Neisseria meningitidis-bakterie er genmodificeret til at tilsikre nedsat eller ingen detekterbar toksisk aktivitet af lipid A.
9. Sammensætning til anvendelse ifølge krav 8, hvor den første Neisseria meningitidis-bakterie er genmodificeret i lipid A-biosyntese, herunder i et gen, der er ansvarligt for terminal modifikation af lipid A.
10. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-9, hvor vesiklerne er fremstillet uden anvendelse af et detergent.
11. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1- 10, hvor den første Neisseria meningitidis-bakterie er Neisseria meningitidis-stamme H44/76.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1- 11, hvor sammensætningen yderligere omfatter: isolerede antigen-vesikler fremstillet ud fra en anden Neisseria meningitidis-bakterie, hvor den anden Neisseria meningitidis-bakterie producerer et niveau af et GNA1870-polypeptid, der er tilstrækkeligt til at tilsikre produktion af vesikler, der, når de indgives til et individ, fremkalder anti-GNA1870-antistoffer, og hvor den anden Neisseria meningitidis-bakterie er genetisk forskellig fra den første Neisseria meningitidis-bakterie.
13. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1- 12, hvor den første bakterie af Neisseria meningitidis-arten er genmodificeret til at producere mindst to forskellige GNA1870-polypeptider af forskellige GNA1870-polypeptidvariantgrupper udvalgt blandt v.1, v.2 og v.3.
14. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-12, hvor GNA1870-polypeptidet er overeksprimeret på et niveau, der er højere end fire gange niveauet af GNA1870-polypeptidet eksprimeret i den paren- talstamme, hvorfra den første Neisseria meningitidis-baklerie er afledt.
15. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-12, hvor GNA1870-polypeptidet er overeksprimeret på et niveau, der er højere end fem gange niveauet af GNA1870-polypeptidet eksprimeret i den pa-rentalstamme, hvorfra den første Neisseria meningitidis-baklerie er afledt.
16. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-12, hvor GNA1870-polypeptidet er overeksprimeret på et niveau, der er højere end otte gange niveauet af GNA1870-polypeptidet eksprimeret i den pa-rentalstamme, hvorfra den første Neisseria meningitidis-bakterie er afledt.
17. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-12, hvor GNA1870-polypeptidet er overeksprimeret på et niveau, der er højere end ti gange niveauet af GNA1870-polypeptidet eksprimeret i den paren-talstamme, hvorfra den første Neisseria meningitidis-bakle ri e er afledt.
DK13172134.2T 2005-01-27 2006-01-23 GNA1870-baserede vesikelvacciner til bredspektret beskyttelse mod sygdomme forårsaget af Neisseria meningitidis DK2682126T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64791105P 2005-01-27 2005-01-27
EP11182969A EP2433647A3 (en) 2005-01-27 2006-01-23 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis

Publications (1)

Publication Number Publication Date
DK2682126T3 true DK2682126T3 (da) 2017-02-27

Family

ID=36741009

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13172134.2T DK2682126T3 (da) 2005-01-27 2006-01-23 GNA1870-baserede vesikelvacciner til bredspektret beskyttelse mod sygdomme forårsaget af Neisseria meningitidis

Country Status (20)

Country Link
US (7) US9034345B2 (da)
EP (3) EP2433647A3 (da)
JP (1) JP4993750B2 (da)
CN (1) CN101107007B (da)
AU (1) AU2006208208B2 (da)
BR (1) BRPI0607374B8 (da)
CA (1) CA2590974C (da)
CY (1) CY1118732T1 (da)
DK (1) DK2682126T3 (da)
ES (1) ES2616294T3 (da)
HK (1) HK1107526A1 (da)
HU (1) HUE033196T2 (da)
LT (1) LT2682126T (da)
MX (1) MX2007008785A (da)
NZ (1) NZ555937A (da)
PL (1) PL2682126T3 (da)
PT (1) PT2682126T (da)
RU (1) RU2432962C2 (da)
SI (1) SI2682126T1 (da)
WO (1) WO2006081259A2 (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1645631E (pt) 1998-05-01 2008-02-04 Novartis Vaccines & Diagnostic Anitigénios da neisseria meningitidis e composições
CN100338218C (zh) 1999-05-19 2007-09-19 启龙股份公司 组合式奈瑟球菌组合物
CA2864069A1 (en) 1999-10-29 2001-05-03 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigenic peptides
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2281571A3 (en) 2000-01-17 2012-04-25 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (omv) vaccine comprising n. meningitidids serogroup b outer membrane proteins
RU2299906C2 (ru) 2000-02-28 2007-05-27 Новартис Вэксинс Энд Диагностикс С.Р.Л. Гетерологичная экспрессия белков neisseria
WO2002009643A2 (en) * 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2695467A1 (en) * 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
EP2200642B1 (en) 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
RU2477145C2 (ru) * 2008-05-30 2013-03-10 ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
AU2009288095A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
AU2015275311B2 (en) * 2008-10-25 2017-07-13 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
MX2011006648A (es) 2008-12-17 2011-10-14 Novartis Ag Vacunas meningococales que incluyen receptor de hemoglobina.
JP5597245B2 (ja) 2009-03-24 2014-10-01 ノバルティス アーゲー アジュバント添加した髄膜炎菌ｈ因子結合タンパク質
WO2010109324A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CN102711814A (zh) * 2009-04-30 2012-10-03 奥克兰儿童医院及研究中心 一种嵌合h因子结合蛋白(fhbp)及其使用方法
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP2494865A4 (en) * 2009-09-01 2014-05-14 Aeon Medix Inc EXTRACELLULAR VESICLES OBTAINED FROM THE DARMFLORA, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE AND CANDIDATE AND DIAGNOSTIC METHOD THEREFOR
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP6166042B2 (ja) * 2009-11-06 2017-07-19 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Ｔ細胞刺激タンパク質ｂおよび使用方法
SG181712A1 (en) 2009-12-15 2012-07-30 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
EP2544713A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20130071422A1 (en) 2010-03-18 2013-03-21 Michele Pallaoro Adjuvanted vaccines for serogroup b meningococcus
KR101853513B1 (ko) 2010-03-23 2018-04-30 노파르티스 아게 감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 ｔｌｒ2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물
BR122021020829B8 (pt) * 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
WO2012002759A2 (ko) * 2010-07-01 2012-01-05 포항공과대학교 산학협력단 세포의 원형질체에서 유래한 마이크로베시클 및 이의 용도
PL3246044T3 (pl) 2010-08-23 2021-08-23 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
EP2613805B1 (en) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
HUE037969T2 (hu) * 2011-07-07 2018-09-28 De Staat Der Nederlanden Vert Door De Mini Van Vws Eljárás gram-negatív baktérium külsõ membrán vezikuláinak detergens-mentes elõállítására
BR112014019166A2 (pt) 2012-02-02 2017-07-04 Novartis Ag promotores para expressão aumentada de proteína em meningococos
EP3485906A1 (en) 2012-03-09 2019-05-22 Pfizer Inc Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2861247B1 (en) 2012-06-14 2020-12-09 GlaxoSmithKline Biologicals SA Vaccines for serogroup x meningococcus
US10000545B2 (en) 2012-07-27 2018-06-19 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
EP4056198A3 (en) * 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
US20160120818A1 (en) 2013-02-07 2016-05-05 Glaxosmithline Biological Sa Pharmaceutical compositions comprising vesicles
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
EA201690056A8 (ru) * 2013-08-02 2017-07-31 Чилдренс Хоспитл Энд Рисерч Сентер Эт Окленд ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2015128480A1 (en) 2014-02-28 2015-09-03 Novartis Ag Modified meningococcal fhbp polypeptides
CN106715464B (zh) 2014-07-23 2021-03-16 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
MX2017010705A (es) 2015-02-19 2017-12-04 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
EP3655031A1 (en) 2017-07-21 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neisseria meningitidis immunogenic compositions
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the
US5075431A (en) 1989-07-26 1991-12-24 City Of Hope Chimeric anti-CEA antibody
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
SG49909A1 (en) 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
ES2333069T3 (es) 1997-03-10 2010-02-16 Ottawa Hospital Research Institute Uso de acidos nucleicos que contienen dinucleotido cpg no metilado en combinacion con alumbre como adyuvante.
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
AU753172B2 (en) 1997-06-06 2002-10-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
DK1047784T4 (da) 1998-01-14 2015-06-15 Novartis Vaccines & Diagnostic Neissera meningitidis-antigener
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
CN1296416A (zh) 1998-04-09 2001-05-23 史密丝克莱恩比彻姆生物有限公司 佐剂组合物
PT1645631E (pt) 1998-05-01 2008-02-04 Novartis Vaccines & Diagnostic Anitigénios da neisseria meningitidis e composições
PT1741443E (pt) 1998-05-29 2014-07-31 Novartis Vaccines & Diagnostic Combinação de vacinas para a meningite b/c
EP1144998A3 (en) 1998-10-09 2002-08-07 Chiron Corporation Neisseria genomic sequences and methods of their use
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
US20030215469A1 (en) 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
NZ511438A (en) * 1998-11-03 2003-03-28 Nederlanden Staat A lipopolysaccharide (LPS) with reduced toxicity from genetically modified gram negative bacteria
US7081244B2 (en) 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
IL145982A0 (en) 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
CA2371032A1 (en) 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001021152A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2281571A3 (en) * 2000-01-17 2012-04-25 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (omv) vaccine comprising n. meningitidids serogroup b outer membrane proteins
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
WO2002009643A2 (en) 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
CA2452836C (en) 2001-07-27 2012-11-27 Chiron Srl Meningococcus adhesins nada, app and orf 40
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP1374892A1 (en) 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
SI1524993T1 (sl) 2002-08-02 2013-07-31 Glaxosmithkline Biologicals S.A. Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
JP4697706B2 (ja) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
CA2695467A1 (en) * 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US8476032B2 (en) * 2008-08-27 2013-07-02 Children's Hospital & Research Center Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis

Also Published As

Publication number Publication date
US9034345B2 (en) 2015-05-19
HUE033196T2 (en) 2017-11-28
CA2590974C (en) 2017-10-03
JP2008528597A (ja) 2008-07-31
CA2590974A1 (en) 2006-08-03
CY1118732T1 (el) 2017-07-12
BRPI0607374A2 (pt) 2009-09-01
PT2682126T (pt) 2017-02-28
JP4993750B2 (ja) 2012-08-08
US20120093867A1 (en) 2012-04-19
US11801293B2 (en) 2023-10-31
BRPI0607374B1 (pt) 2020-04-22
US20200138931A1 (en) 2020-05-07
EP1855715A2 (en) 2007-11-21
HK1107526A1 (en) 2008-04-11
RU2432962C2 (ru) 2011-11-10
EP1855715B1 (en) 2013-03-13
CN101107007B (zh) 2011-08-17
NZ555937A (en) 2009-05-31
US10857221B2 (en) 2020-12-08
US8968748B2 (en) 2015-03-03
US10478484B2 (en) 2019-11-19
US20150290312A1 (en) 2015-10-15
US20080248065A1 (en) 2008-10-09
EP2433647A3 (en) 2012-06-06
BRPI0607374B8 (pt) 2021-05-25
AU2006208208A1 (en) 2006-08-03
LT2682126T (lt) 2017-02-27
US10046043B2 (en) 2018-08-14
EP2682126B1 (en) 2016-11-23
US20180369356A1 (en) 2018-12-27
AU2006208208B2 (en) 2011-05-19
RU2007128332A (ru) 2009-01-27
EP2682126A1 (en) 2014-01-08
EP1855715A4 (en) 2009-06-17
SI2682126T1 (sl) 2017-03-31
PL2682126T3 (pl) 2017-07-31
CN101107007A (zh) 2008-01-16
MX2007008785A (es) 2008-02-15
WO2006081259A2 (en) 2006-08-03
US20170065699A1 (en) 2017-03-09
EP2433647A2 (en) 2012-03-28
ES2616294T3 (es) 2017-06-12
US9452208B2 (en) 2016-09-27
US20210308247A1 (en) 2021-10-07
WO2006081259A3 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
US11801293B2 (en) GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US20090035328A1 (en) fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
CA2416137C (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
JP2016040289A (ja) キメラ因子ｈ結合タンパク質（ｆｈｂｐ）およびその使用方法
EP2552942A1 (en) Factor h binding proteins (fhbp) with altered properties and methods of use thereof